November 25, 2025 a 07:43 pm
PODD: Fundamental Ratio Analysis - Insulet Corporation
Insulet Corporation, headquartered in Acton, Massachusetts, is a key player in the medical devices sector with its innovative Omnipod System. Given its solid presence in global markets like the US, Europe, and beyond, its fundamental ratios reveal a company with both opportunities and areas needing close management.
Fundamental Rating
The fundamental rating of Insulet Corporation, marked at B-, suggests a stable financial footing with potential for growth. Let's dive into the specific categories and scores for a clearer picture.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 1 | |
| Return on Equity | 4 | |
| Return on Assets | 5 | |
| Debt to Equity | 2 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
Examining historical data gives us insights into the corporation's financial progress over time. Here, we compare the current scores with those from previous assessments.
| Date | Overall Score | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-11-25 | 2 | 1 | 4 | 5 | 2 | 1 | 1 |
| Previous | 0 | 1 | 4 | 5 | 2 | 1 | 1 |
Analyst Price Targets
Analyst predictions for Insulet's stock price reflect positive sentiment, with the consensus set at a "Buy".
| High | Low | Median | Consensus |
|---|---|---|---|
| $432 | $301 | $400 | $386.43 |
Analyst Sentiment
The analyst sentiment remains favorable, with a dominant number of "Buy" recommendations suggesting confidence in Insulet's future growth.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 31 | |
| Hold | 12 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Insulet Corporation shows a promising potential for investors with its innovative insulin delivery systems. While the current fundamental analysis indicates areas for financial improvement, the positive analyst sentiment and strong buy recommendations signify confidence in the company's future. The ongoing development and market reach of the Omnipod System bolster its competitive edge. However, investors should remain cautious of the inherent risks associated with medical device manufacturing and global distribution challenges.